财新传媒
财新英文 > 要闻 > 正文

In Depth: Drugmakers Under Pressure as Beijing Drives a Hard Bargain

By Zhou Xinda, Hua Ang and Kelly Wang
2024年12月27日 20:45
The latest round of bulk drug-buying for China’s national health care system saw some of the steepest price cuts yet
The latest round of China’s bulk drug procurement has seen some of the steepest price cuts yet, far exceeding bidders’ expectations. Photo: AI generated

Sighs echoed around the room when the assembled pharmaceutical industry representatives heard some of the bidding prices for their drugs, Wang Yu told Caixin.

The round of bulk drug procurement, the 10th since the scheme was launched nationwide in 2019, saw some of the steepest price cuts yet, with over 50 out of 385 products purchased reportedly seeing an over 90% price cuts, sparking concerns about product quality and the industry’s long-term development.

  [财新双语通产品,是为有双语需求读者专门订制的优惠产品, 按此可享超值优惠订阅。]

版面编辑:喻竹杨洋
财新网主编精选版电邮 样例
财新网新闻版电邮全新升级!财新网主编精心编写,每个工作日定时投递,篇篇重磅,可信可引。
订阅